Bio-Path (NASDAQ:BPTH) Stock Price Passes Above 200-Day Moving Average of $1.62

Bio-Path Holdings, Inc. (NASDAQ:BPTH – Get Rating) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.62 and traded as high as $1.74. Bio-Path shares last traded at $1.71, with a volume of 30,799 shares.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Roth Capital reiterated a “buy” rating on shares of Bio-Path in a research note on Friday, March 17th. StockNews.com assumed coverage on Bio-Path in a report on Wednesday. They set a “sell” rating on the stock.

Bio-Path Stock Up 2.4 %

The business’s 50-day moving average price is $1.48 and its 200 day moving average price is $1.62. The company has a market capitalization of $13.61 million, a P/E ratio of -0.81 and a beta of 1.30.

Bio-Path (NASDAQ:BPTH – Get Rating) last released its quarterly earnings results on Friday, March 31st. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.08). Analysts anticipate that Bio-Path Holdings, Inc. will post -1.91 EPS for the current fiscal year.

Institutional Investors Weigh In On Bio-Path

Several hedge funds have recently bought and sold shares of BPTH. Mount Yale Investment Advisors LLC bought a new stake in Bio-Path during the third quarter worth about $81,000. Renaissance Technologies LLC bought a new stake in shares of Bio-Path in the 2nd quarter worth approximately $70,000. Virtu Financial LLC purchased a new stake in shares of Bio-Path in the 1st quarter valued at $38,000. Finally, Citadel Advisors LLC bought a new position in shares of Bio-Path during the 3rd quarter valued at $35,000. 6.42% of the stock is currently owned by institutional investors.

About Bio-Path

(Get Rating)

Bio-Path Holdings, Inc is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.